Furthermore, Wang et al. [33] reported that a phase 2, open-label, single-arm clinical trial of CD133-targeted chimeric antigen receptor T (CAR-T) cell treatment was effective and safe for patients with advanced HCC. This evidence concerns the gene PROM1 and hepatocellular carcinoma.